Home
overview

 
 

SMi's Cell-Based Assays conference is now in its 3rd year - click here to view our 2010 event 

 

 


 
2008 Past Event Details:

Cell-based assays monitor changes in living cells in response to a wide variety of inducers and events, such as receptor activation, external stimuli and stress, drugs, and modulated gene and protein expression. The market for these assays and their applications is growing rapidly, with new advances in technology platforms and high throughput screening systems. Recent studies by the MRG reveal a 40% growth from last year, with the worldwide market worth a phenomenal $1.6 billion in 2007. The expansion of the cell-based assays market is derived from the need for elucidating the functions of millions of proteins, and for better medicine development. By employing bioassays in automated systems, characterisation of a large number of drug targets can be streamlined and the drug discovery process made more efficient. 
 
Cell-based assays are used in both academia and pharmaceutical R&D, and are an integral part of preclinical drug development.  Bioassays increasingly facilitate the link between laboratory and clinic by identifying adverse effects.  It is an optimum time to discover the techniques and methods you need to succeed with cell-based assays. SMi's Cell-Based Assays conference is designed to convey this knowledge and to reveal the latest technological developments in the area.

 
 

 

 
Critical challenges that will be addressed:
  • BIOASSAY DEVELOPMENT:  Examine the requirements for efficient cell-based assay development
  • NEW AND IMPROVED TECHNOLOGY PLATFORMS: Gain an insight into the latest advances in the technologies behind cell-based assays from imaging to biosensors
  • CELL-BASED ASSAY APPLICATIONS: Explore the versatility of cell based assay applications in a multitude of fields
  • HIGH THROUGHPUT CELL-BASED SCREENING:  Understand multi-parallel, high throughput and array systems of cell-based assays and applications
  • EXPANDING THE POTENTIAL: From detection methods and reporter assays to gene and protein function and drug target discovery

 

 

 
Expert speaker line-up includes:
 
 
  • Oliver Nayler, Director, Head Molecular Cell Biology, Actelion Pharmaceuticals Ltd
  • Willem Schoonen, Group Leader In Vitro Toxicology and Toxicogenomics, DMPK & Safety, Schering Plough Research Institute
  • Rami Hannoush, Scientist, Protein Engineering, Genentech Inc
  • Paul Lang, Head, Assay Development and Biomolecular Pharmacology, Merck Serono
  • Marie-Claire Peakman, Senior Director, Cardiovascular, Metabolic and Endocrine Disease, Pfizer Global R&D
  • Alison Griffen, Associate Team Leader, Cancer Bioscience, AstraZeneca
  • Khalid Khabar, Director, Biomolecular Research, King Faisal Specialist Hospital and Research Centre
  • Philip Denner, Screening, High-Content Analysis, Lead Discovery, Bayer Schering Pharma AG
  • Vincent Unterreiner, Novartis Pharma AG
  • David Ferrick, Chief Scientific Officer, Biology and Applications, Seahorse Bioscience Inc
  • Laleh Safinia, Research Analyst, Frost & Sullivan
  • Rob Howes, Research Director, Horizon Discovery Ltd
  • Heather Baird Tomlinson, Senior Manager, Pharmaceutical Products, Diagnostic Hybrids
  • Rosalyn Forsey, Biomarker Specialist, LCG Biosciences
  • Rochdi Bouhelal, Research Investigator, Novartis Pharma AG
  • Debbie Lane, Team Leader, High Throughput Screening, Research, Medimmune
  • Patricia Harris, Executive Director of Worldwide Sales, Sales and Marketing, Diagnostic Hybrids
  • Andreas Scheel, Head, Cellular Assays, Evotec AG
  • Yoram Reiter, Head, Laboratory of Molecular Immunology, Technion - Israel Institute of Technology
  • Daniel D’Orazio, Research Investigator, Centre for Proteomic Chemistry / Expertise Platform Kinases, Novartis
  • Catherine Booth, Founder and MD Contract Research Services, Epistem Ltd
  • Maria Torvinen, Field Application Scientist,Corning

     

 


 

 

 
You will benefit from attending this event if you are:

 
 
A Vice President, Director or Group Leader from within the pharmaceutical or biotech industry with responsibilities in the following areas:
 
  • Disease profiling
  • Drug target discovery / validation
  • Drug discovery
  • ADMET
  • Preclinical development
  • Pharmacokinetics
  • Drug metabolism
  • Toxicology
  • Clinical research
  • Screening
  • Functional genomics
  • Medicinal chemistry
  • Lead optimisation
  • Structural biology
  • Molecular and cell biology
  • Proteomics
  • Biopharmaceuticals research
  • Bioanalytical development
  • Kinase and GPCR assays
  • Diagnostics
  • Bioassay development / optimisation

 



 

For Speaking opportunities please contact Jill Jouret at jjouret@smi-online.co.uk
For Sponsorship opportunities please contact Alia Malick at amalick@smi-online.co.uk

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Rami  Hannoush

Rami Hannoush, Scientist, Genentech

9:10 KEYNOTE PRESENTATION: AN OVERVIEW

Khalid Khabar

Khalid Khabar, Director, Biomolecular Program, Faisal Specialist Hospital & Research Centre

  • Key elements of cell-based assays
  • Overview of technologies used and applications
  • Expanding possibilities and market trends
  • Examples from real laboratory life
  • 9:40 THE CELL-BASED ASSAYS MARKET

    Laleh Safinia

    Laleh Safinia, Research Analyst, Frost & Sullivan

  • Identification of challenges and drivers  facing the European cell-based assays market
  • Forecasts for the European cell-based assays market
  • Technology and end-user trends for the European cell-based assays market
  • Strategic recommendations for the European cell-based assays market
  • 10:10 Morning Coffee

    10:40 ANTIBODY ASSAYS

    Yoram  Reiter

    Yoram Reiter, Head, Laboratory of Molecular Immunology, Technion - Israel Institute Of Technology

    11:10 HIGH CONTENT SCREENING THROUGH FLOW CYTOMETRY

    Abder Mahfoudi

    Abder Mahfoudi, Head of Business Development, Fluofarma

  •                Fully Automated flow cytometry platform for High Content Screening
  •                Cell-based assays and multiplexed functional readouts in single cells
  •                Biosensors for the quantitative analysis of target protein localization and activity, using flow cytometry
  •                Improving the throughput and screening content for in vitro target validation
  •                Multiparametric profiling of anti-cancer drugs
  • 11:50 HIGH-CONTENT ASSAYS: MULTIPARAMETER IMAGING ASSAYS FOR CNS RESEARCH

    Andreas Scheel

    Andreas Scheel, Head, Cellular Assays, Evotec

  • Pathway and phenotypic read-outs for compound screening
  • Use of cell lines and primary neurons
  • Multiparameter read-outs
  • Computational tools for data analysis
  • 12:20 Networking Lunch

    13:20 ION CHANNELS ASSAYS

    Rochdi Bouhelal

    Rochdi Bouhelal, Research Investigator, Novartis Pharma

    13:50 PROFILING P53 NETWORKS BY CELL-BASED MULTIPLEX IMAGING

    Rami  Hannoush

    Rami Hannoush, Scientist, Genentech

  • A multiplex cell-based imaging assay was developed to detect cellular activation of p53
  • Using the above assay, RNA interference and small molecule screens were conducted in parallel to identify regulators of the p53 pathway
  • These results lead to a systems understanding of the p53 interaction network and to identifying novel therapeutic targets
  • 14:20 APPLICATION OF FROZEN CELLS

    Alison Griffen

    Alison Griffen, Associate Team Leader, Astrazeneca

  • Benefits and limitations
  • Impact on time, resources and data accuracy
  • Batch to catch consistency
  • Cryopreservation of transiently transfected cells
  • 15:00 Afternoon Tea

    15:30 INNOVATIVE TISSUE CULTURE MODELS TO PREDICT DRUG EFFICACY

    Catherine Booth

    Catherine Booth, Founder and MD Contract Research Services, Epistem

  • Cancer stem cell and angiogenesis models
  • Skin and intestinal models
  • Improved candidate selection, earlier identification of adverse effects
  • Proof of concept / mechanism of action
  • 16:00 ADAPTING COMPLEX HIGH CONTENT IMAGING ASSAYS TO HIGH DENSITY FORMATS

    Vincent Unterreiner

    Vincent Unterreiner, Scientist, Center for Proteomic Chemistry, Novartis Pharma

    • High content screening in 1536 well plate format
    • Infrastructure needed to perform non homogenous imaging assays (devices and automated platforms)
    • Cell migration assay implementation into screening format

    16:30 ONCOLOGY ASSAYS

    Rob Howes

    Rob Howes, Research Director, Horizon Discovery

  • Key issues to consider
  • Recent developments in the field
  • Analysing novel methodologies
  • Advantages of automation
  • Integration of cell based assays with in vivo models of cancer
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Khalid Khabar

    Khalid Khabar, Director, Biomolecular Program, Faisal Specialist Hospital & Research Centre

    9:10 CONSIDERING HIGH-CONTENT SCREENING AND LABEL-FREE SCREENING TO MAKE THE BEST SCREENING CHOICES

    Dominique Perrin

    Dominique Perrin, Group Leader, Molecular and Cellular Lead Discovery, Merck Serono

  • Screening strategies
  • Profiling experiments and the application of the acquired data
  • Analysing the specificity of antibodies against other receptors
  • Evaluating detection technology
  • 9:40 APPLICATIONS AND STRATEGIES FOR GPCR IMPEDANCE ASSAY TECHNOLOGIES USING PRIMARY CELLS

    Oliver Nayler

    Oliver Nayler, Director, Head of Molecular Biology, Actelion

  • Primary versus recombinant cells
  • Label-free assays
  • Are pathway predictions possible
  • 10:10 PRINCIPLES AND APPLICATIONS OF LABEL-FREE CELL BASED ASSAYS USING THE CORNING® EPIC® SYSTEM

    Maria Torvinen

    Maria Torvinen, Field Application Scientist, Corning

  • Benefits of Label-Free Detection
  • Dynamic Mass Redistribution - What do we measure?
  • Detection of integrated cellular pathways in one shot - what are you missing with more conventional detection methods?
  • Examples of Epic® cell based assays
  • 10:50 Morning Coffee

    11:20 HIGH THROUGHPUT SCREENING ANALYSIS FOR GENOTOXICITY AND CLASTOGENICITY

    Willem Schoonen

    Willem Schoonen, Group Leader, Schering-Plough Research Institute

  • Genotoxicity screening with Salmonella: comparison of the VitotoxTM test with literature data for the full Ames test
  • Clastogenicity screening with yeast: comparison of the GreenScreen GC and RadarScreen tests with literature data from in vitro micronuclei and chromosomal aberration tests
  • Clastogenicity screening with human liver HepG2 cells: comparison of three different promoter settings involved in chromosomal repair
  • 11:50 HIGH THROUGHPUT SCREENING OF BIOLOGICS

    Paula Harrison

    Paula Harrison, Head of High Throughput Screening, Medimmune

  • Assays used to screen for functional antibodies
  • Challenges of screening un-purified biologics in cell-based assays
  • Characterisation of purified biologics
  • Implementing cell-based assays in the future
  • 12:20 Networking Lunch

    13:20 CELL CULTURE SOLUTIONS FOR YOUR LABORATORY

  • Complete detection systems for respiratory viruses, herpesviruses, enteroviruses
  • ELVIS® Flu cell system for influenza serum neutralisation assays and TCID50 determination
  • Primary hepatocytes for in vitro toxicology applications
  • Other continuous cell lines and MAb’s for your applications
  • Heather Baird Tomlinson

    Heather Baird Tomlinson, Senior Manager, Diagnostic Hybrids

    Patricia Harris

    Patricia Harris, Executive Director of Worldwide Sales, Diagnostic Hybrids

    14:00 HIGH CONTENT SCREENING

    Philip Denner

    Philip Denner, Scientist, Screening High-Content Analysis, Bayer Schering Pharma

  • The use of imaging based assays and assessing their suitability
  • Quantifying different cellular responses and phenotypes
  • Analysis cell counting, translocation, angiogenesis and cell apoptosis
  • Analysis techniques, data management and dye choices
  • 14:30 CELLULAR BIOENERGETICS IN A MICROPLATE: A NEW WINDOW ON METABOLISM

    David Ferrick

    David Ferrick, Chief Scientific Officer, Biology and Applications, Seahorse Bioscience

  • Real time measurements of aerobic metabolism and glycolytic flux
  • Designing complex experiments using automated drug injection ports
  • Cells can be grown/differentiated and analysed in the same microplate
  • Using bioenergetics to measure growth, differentiation and cell death
  • 15:00 Afternoon Tea

    15:30 DRIVING DRUG DISCOVERY PROGRAMS WITH PRIMARY PHARMACOLOGY DATA FROM CELL-BASED ASSAYS

    Simon Eaglestone

    Simon Eaglestone, Senior Principal Scientist, Pfizer Global R&D

  • Incorporation of cell-based assays into in vitro screening strategies for drug discovery
  • Comparison of alternate assay formats, challenges and caveats
  • Optimisation of efficiency and data quality
  • Data analysis, integration and visualisation
  • 16:00 CELL-BASED BIOMARKERS: A FRESH APPROACH

    Rosalyn Forsey

    Rosalyn Forsey, Biomarker Specialist, LCG Bioscience

  • Flow cytometry
  • Multiplex analysis
  • Cytokines
  • Ex vivo stimulation
  • 16:30 AN INTEGRATED APPROACH TO KINASE INHIBITORS PROFILING

    Daniel D’Orazio

    Daniel D’Orazio, Research Investigator, Centre for Proteomic Chemistry / Expertise Platform Kinases, Novartis

  • Signalling pathway profiling using RGAs
  • Signalling pathway analysis using phosphoproteomics technologies
  • Beta lactamase reporter gene assays
  • Reverse Protein Arrays
  • Multiplexing readouts
  • Illustrative examples
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    Khalid Khabar

    Khalid Khabar, Director, Biomolecular Program, Faisal Specialist Hospital & Research Centre

    +

    Workshops

    Novel Rapid Cell Methods in Diagnostics and Toxicology / Pharma Applications
    Workshop

    Novel Rapid Cell Methods in Diagnostics and Toxicology / Pharma Applications

    Crowne Plaza Hotel - St James
    18th November 2008
    London, United Kingdom

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.